Nektar Therapeutics is an American biopharmaceutical company headquartered in San Francisco. It develops drug candidates across multiple therapeutic areas and applies polymer conjugate and PEGylation-based technologies to improve drug properties.
Nektar said extended rezpeg treatment promoted greater hair growth in severe alopecia areata and reported durable 52-week efficacy for rezpegaldesleukin in atopic dermatitis. The company said it has FDA alignment on Phase 3 design and is targeting a BLA submission by 2029.
Nektar Therapeutics is advancing its immunology pipeline with plans to initiate Phase 3 trials for REZPEG in atopic dermatitis next quarter, following positive Phase 2b results. The company recently completed a large equity raise to support its regulatory T cell-focused programs.
The alopecia areata treatment market is projected to grow significantly through 2036, driven by rising prevalence and the anticipated launch of emerging therapies including JAK inhibitors and novel drug classes targeting immune pathways.
Nektar Therapeutics completed a $460 million public offering on February 13, 2026, selling 7.6 million shares of common stock and pre-funded warrants. The clinical-stage biotechnology company is developing immunotherapy treatments for autoimmune diseases.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07711418 |
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis |
RECRUITING | PHASE3 |
| NCT07690371 |
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis |
RECRUITING | PHASE3 |
| NCT06340360 |
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA) |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06136741 |
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT05676749 |
C-TIL051 in Non-Small Cell Lung Cancer |
TERMINATED | PHASE1 |
| NCT05664217 |
NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma |
TERMINATED | PHASE2/PHASE3 |
| NCT05632809 |
REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE) |
RECRUITING | PHASE2 |
| NCT05565729 |
A Phase I Study of LY3471851 in Healthy Participants |
COMPLETED | PHASE1 |
| NCT05359211 |
NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT04998487 |
A Single-Dose Study of LY3471851 in Healthy Participants |
COMPLETED | PHASE1 |
